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Snnlnlary 
Intravenous  infusion of mice with major histocompatibility complex (MHC)  incompatible 
lymphocytes can inhibit the response of recipient  T  cells capable of recognizing the injected 
cells, and can enhance survival of grafts sharing MHC with the injected cells. However, neither 
T cell inactivation nor graft survival enhancement is always achieved. This is particularly true 
for donor cells that are fully allogeneic (as compared to semiallogeneic) to the recipient. We 
show here that both donor-specific induced response reduction and graft survival enhancement 
are directly correlated with the ability of the injected lymphoid cells to persist in the recirculating 
lymphocyte pool of the host. Whether donor cells persist correlates inversely with the level of 
natural killer cell (NK) activity in the host. Fully allogeneic cells can only persist in hosts with 
low NK activity and can then induce response reduction. Both persistence and response reduction 
are abrogated by injection of the host with polyI:C, a treatment that boosts host NK activity. 
The same treatment also destroys the ability of semiallogeneic injected cells to persist, to induce 
response reduction, and to enhance skin graft  survival. 
I 
'ntravenous  injection of mice with viable aUogeneic lyre- 
. phoid cells can produce a donor-specific reduction in the 
ability of the mice to proliferate  (1), generate CTL (2-6), 
and generate Th (7) in a subsequent MLR, and can also en- 
hance survival of a graft syngeneic to the lymphoid cell donor 
(6, 8-10). One possible explanation is that the injected donor 
lymphoid cells act as deletional APC or veto cells (11-15) 
and produce fimctional deletion rather than activation of host 
lymphocytes that recognize them (3-8). However, if this hy- 
pothesis  is correct, an explanation  for the following must 
be found. As reviewed elsewhere (7), injection of viable semi- 
allogeneic F1 (A  x  B) lymphoid cells into either parent A 
or parent B usually (but not always) induces response reduc- 
tion and/or enhanced graft survival. However, injection of 
fully allogeneic B lymphoid cells into A seldom induces ei- 
ther response reduction or enhanced graft survival, although 
the veto hypothesis  predicts  it should occur. 
Previous work from this laboratory has shown that when 
B6D2F1 lymphoid cells are injected into B6 recipients, they 
induce a donor-specific inactivation of both CTLp (5) and 
Thp (7). The lymphoid cells to be injected were first FITC 
labeled,  and could thus by easily detected and enumerated 
in the host by flow cytometry. It was thus found that the 
injected cells persisted in the host for at least 10 d and ap- 
peared to have entered the recirculating lymphocyte pool. 
Using the same methodology, we show here that those lym- 
phoid cells which, on injection, fail to induce response reduc- 
tion,  also disappear in <3 d from the recirculating pool, 
whereas those that do induce response reduction are still readily 
detectable on day 3. Cells that fail to persist in the recirculating 
pool appear to be removed by an active process, possibly NK- 
cell mediated. A similar correlation appears to govern whether 
injected F1 lymphoid cells can enhance F1 skin graft survival 
on a parent. 
Materials and Methods 
Mic~  (C57BL/6  x  DBA/2)F1 (B6D2Ft, H-2b/a), C57BL/6 
(/36, H-2b), DBA/2  (D2, H-2d), SJL  (1-I-2'), SWR  (H-2q), 
C57BL/6-beige  (B6-bg, H-2b), C57BL/6-nude  (B6-nu), and 
BALB/c-nude were from The Jackson  Laboratory  (Bar Harbor, ME). 
All mice were used at least I wk after delivery  at an age of 7-12 
wk and were maintained  under specific  pathogen-free  (SPF)  1  con- 
ditions. 
Preparation  and Infusion of  Donor Cells.  Lymphoid  cells  were pre- 
pared by gently pressing spleen and pooled cervical, inguinal, and 
mesenteric lymph nodes through a wire mesh into our complete 
medium (CM). This consists ofcxMEM supplemented  with 10% 
(vol/vol) FCS (Gibco, Grand Island, NY), 5  x  10 -s M 2-ME 
(Eastman Kodak Co., Rochester, NY) and 10 mM Hepes buffer 
(Sigma Chemical  Co., St. Louis, MO). The cells  were then washed 
1 Abbreviations used in this  paper: ALC, allogenic lymphocyte cytotoxicity; 
CM, complete medium; LNC, lymph node cell; polyI:C, polymerized 
inosine, cytidine; and SPF, specific  pathogen-free. 
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5  ml lympholyte-M (Cedarlane Laboratories,  Horaby, Ontario, 
Canada), and centrifuged at 500 g for 30 min to remove red blood 
and dead cells. After washes in CM, a FITC solution (30/~g/ml 
PIE final)  was added to 4-6  x  107 cells in  1 ml PIE, and in- 
cubated at 37~  in an 11% CO= incubator. Excess FITC was re- 
moved by centrifuging the cells through 3 ml 6% lEA/PIE. After 
two more washes  in 1% lEA/PIE, 3  x  107 cells in 0.3 ml 1% 
lEA/PIE were injected into the lateral tail vein of recipient mice. 
Entry of FITC-hbeled donor cells into the lymphocyte recirculating 
pool  was  monitored by  killing  recipients  after  injection,  and 
preparing suspensions  of blood, lymph nodes, or spleen cells, and 
analyzing them on a Becton Dickinson & Co. FACScan  |  flow 
cytometer. 
Treatment of Host with Pol~aerized Inosine:CTtidine (polyI:C) or 
AGMI.  PolyI:C (100/~g, Sigma Chemical Co.) in 0.3 ml PIE 
was administered intrapedtoneally into each mouse 30--60 min after 
donor cell infusion, and again 1 d hter. 50/~g antiasialo GM1 (rabbit) 
(AGM1,  Wako Chemicals USA, Dallas,  TX) in 0.3 ml PIE was 
injected intraperitoneally into each mouse 1 d before donor cell 
infusion. 
MLR and Cytotoxiciff Assay.  Standard MLR conditions were 
used as previously described (5, 7). Briefly three titrations of re- 
spender lymph node cells (LNC) (10  s, 3  x  104, 104) in five repli- 
cates were cultured with 3  x  10  s irradiated (2,000 tad) stimulator 
spleen cells in 96-well  V-bottomed plates in 0.2 ml CM for 5 d 
at  37~  in  an  11%  CO=  incubator.  To  overcome  possible 
deficiency in help, mouse rll.,2 culture supernatant (SN) (2 U/ml 
final) was added (16). The cultures were tested for cytotoxic ac- 
tivity in a standard 4-h SlCr-release assay using appropriate Con 
A splenobhsts as targets. Con A blasts were prepared by culturing 
107 spleen cells in 10-ml CM in flasks with 4/~g/ml Con A for 
2-3 d, centrifuging over lympholyte-M and washing twice in CM 
containing 20 mM 2-methyl-D-mannoside. Individual cultures re- 
ceived 2,000 target cells labeled with Na SlCrO4 (New England 
Nuclear, Boston, MA) as described (5, 7). The fractional specific 
lysis was measured as [(Experimental release  -  spontaneous re- 
lease)/(Total release  -  spontaneous release)]. 
Tail Skin Grafting.  This was done as described by Kast et al. 
(8). Briefly, pieces of donor tail skin ,,o4 x  8 mm and of a thick- 
ness including the epidermis and most of the dermis were removed 
with a sharp scalpel and transferred to sites on the recipient tail 
from which an equivalent amount of skin had been removed. Grafts 
were covered with a clear spray bandage (New-Skin, Medtech Labs, 
Jackson, WY) and further protected with a light, loosely fitting 
transparent glass tube slipped over the tail and held in place with 
masking tape. Tubes were removed 7-10 d after grafting. Each re- 
cipient received two skin grafts, experimental and control, placed 
lengthwise along the taft,  and separated  by about 5 mm. Grafts 
were visually monitored daily and scored as rejected when >90% 
dead. 
Results 
Induced Donor.specific Response Reduction Is Correlated with 
Donor Cell Recirculation.  D2 mice were injected intravenously 
with 3  x  10  v FITC-labded viable B6D2F1 lymphoid cells 
and killed 3  d  later.  Lymph node cells were tested in an in 
vitro MLR for their ability to generate CTL, and were also 
checked by flow cytometry for the presence of FITC-labeled 
donor cells. Fig.  1 A  (left) shows that FITC-labeled F1 cells 
can be detected in the LN cells where they comprise 2.5% 
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Figure 1.  Continued presence  of injected foreign lymphoid cells is cor- 
rehted with their ability to induce donor-specific  response reduction. Re- 
cipient mice were injected intravenously  with 3 x  107 FITC-labeled  for- 
eign lymphoid cells. 3 d later, mice were killed and LN cells analyzed for 
the presence of FITC-hbeled cells by flow cytometry (left, forward  angle 
light scatter  (FSC) vsfluorescence)  and for their ability to generate  CTL against 
donor stimuhtor cells (middle) and unrelated third party stimulator cells 
(right) in a 5-d MLR. The MLR data are shown as cytotoxic activity de- 
veloped by 104, 3  x  104, or 10  s responder cells from injected (solid bars) 
or control (open bars) mice. (.4) B6D2Ft lymphoid cells injected into D2 
recipients; (B) D2 lymphoid cells injected into B6 recipients; (C) D2 lym- 
phoid cells (from same pool as in B) injected into B6-bg/bg recipients; 
(D) B6 lymphoid cells injected into SJL recipients; (E) ]36 lymphoid cells 
injected into polyI:C-treated SJL recipients. D and E were done at the 
same time using the same donor pool and matched recipients; and (F) 
B6D2F1 lymphoid cells injected into polyI:C-treated  D2 recipients. A and 
F were done at the same time using the same donor pool and matched 
recipients. 
of all cells.  As argued previously (5),  these cells appear  to 
have entered the recirculating lymphocyte pool of the D2 host. 
The antidonor (anti-F  0  CTL response of these LN cells was 
reduced compared to uninjectedcontrols (Fig. 1 A, middle) 
whereas the CTL response against a third party (SWR) was 
unaffected (Fig. 1 A, right).  Similar results were seen on in- 
jecting  FITC-labeled  B6D2F1  lymphocytes  into  B6  mice 
(not show,  n), in agreement with previous work, i.e., the in- 
jected cells entered the recirculating pool (5) and produced 
a  donor-specific response reduction  (2-7). 
Injection orB6 mice with (fully allogeneic) D2 or BALB/c 
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LN  Spleen  Blood 
Donor-Host  Day  1  Day  2  Day  1  Day  2  Day  1  Day  2 
D2-D2  4.4  +  0.2  4.9  _+  0.4  4.8  _+  1.0  4.4  +  0.2  2.0  +  0.3  0.9  _+  0.1 
D2-B6  1.9  _+  0.1  0.05  _+  0.01  2.6  _+  0.2  0.04  +  0.01  1.3  _+  0.2  0.04  +  0.03 
3  x  107 FITC-labeled D2 lymphoid cells were infused into D2 or 136 mice. 1 or 2 d later, host LN, spleen,  and blood cells were analyzed by flow 
cytometry. The table lists mean  +  SD percent PlTC-labeled cells obtained from two different experiments. 
lymphoid cells does not induce response reduction (7) even 
though the differences potentially detectable by the host on 
the injected cells are identical to those seen when B6D2F1 
lymphoid cells are injected. We injected 3  x  107 FITC- 
labeled D2 lymphoid cells into B6 mice. 3 d later, mice were 
killed and their LN cells tested as above. In agreement with 
previous results, no donor-specific response reduction was seen 
(Fig.  1 B). However, we also found that the injected cells 
could not be detected in LN (Fig.  1 B), i.e., they were not 
in the recirculating lymphocyte pool. 
We reasoned that the failure to detect FITC-labeled D2 
cells in B6 LN after injection into B6 mice was either be- 
cause the injected cells could not enter the lymphocyte recir- 
culating pool and would thus stay in blood for some time, 
or that they were being rapidly removed. The latter appears 
to be the case. HTC-labded allogeneic donor cells were de- 
tected in LN and spleen 1 d after injection, i.e, they could 
enter the recirculating pool, but had disappeared from these 
tissues  as well as from blood by day 2 (Table 1). 
It is possible that fully allogenic donor cells are being re- 
moved by host NK cells. B6 mice homozygous for the beige 
Table  2.  Persistence of Fully Allogeneic Donor Cells Correlates 
Inversely with Host NK Activity 
Percent donor 
Host  PolyI:C  AGM1  cells in LN 
Expt.  1  B6-bg  -  -  4.2  _+  0.3 
SJL  -  -  1.7  +  0.2 
B6  -  -  0.02  +  0.01 
B6  -  +  4.3  +  0.03 
SJL  +  -  0.03  _+  0.01 
Expt.  2  B6-nu  -  -  0.24  _+  0.08 
BALB/c-nu  -  -  5.4* 
D2  -  -  7.5" 
mutation have very low levels of NK activity (17), and NK 
activity of SJL mice is known to be less than half that of 
B6 mice (18). We injected 3  x  107 FITC-labeled BALB/c 
lymphocytes into B6-bg, SJL, and B6 hosts. 3 d later, host 
LN cells were tested for the presence of donor cells by flow 
cytometry. One sees (Table 2) that the injected cells were de- 
tected in B6-bg and SJL LN, but not in B6 LN, which is 
consistent with NK cells being responsible for removing the 
cells. As a direct test that host T cells were not responsible, 
we injected D2 cells into B6-nu mice. They were rapidly re- 
moved (Table 2, Expt. 2). 
In vivo administration of antiasialo GM1 antibody is known 
to decrease NK activity (19). When B6 mice were treated 
with this antibody, BALB/c donor cells could be found in 
LN 3 d later (Table 2).  In vivo administration of polyI:C 
is known to increase endogenous NK activity (20). We there- 
fore tested the effect of poly I:C treatment on SJL mice in- 
jected with BALB/c lymphoid cells (Table 2), and on D2 or 
B6 mice injected with B6D2FI lymphoid cells (Table 3). In 
both cases, polyI:C treatment led to disappearance of donor 
cells from LN when tested 3 d after injection of the lym- 
phoid cells (Tables 2 and 3).  Note that polyI:C treatment 
had no influence on syngeneic donor cell redrculation (Table 3). 
We next asked whether fully allogeneic ceils that enter the 
recirculating lymphocyte pool will also induce donor-specific 
response reduction. B6-bg mice were infused with 3  x  10  7 
FITC-labded D2 lymphocytes. 3 d later, both donor cell recir- 
Groups of three recipients were infused with 3  x  107 FITC-labeled 
BALB/c (Expt.  1) or 4  x  107 PlTC-hbeled D2 (Expt. 2) lymphoid cells 
with or without polyI:C or AGM1 treatment as indicated. 3 d  later, 
recipient LN were analyzed by flow cytometry for percent donor cells. 
* Single recipient. 
Table 3.  PolyI:C Treatment of Host Influences Persistence 
of Semiallogeneic but Not Syngeneic Donor Cells 
Donor cells in LN 
Host  No  treatment  PolyI:C-treated 
D2  2.5  +  0.2  0.01  _+  0.01 
B6  1.6  _+  0.5  0.01  +  0.02 
B6D2F1  4.9  _+  0.1  4.9  _+  0.2 
In each group,  three mice were infused with 3  x  107 FITC-labeled 
B6D2F1  lymphocytes with or without polyI:C treatment as indicated. 
3 d later, LN cells were analyzed by flow cytometry for percent donor cells. 
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Figure 2.  Skin  graft survival  after  intravenous  injection  of foreign  lym- 
phoid cells. Groups of D2 mice  were  infused  with 3 x 107 B6D2F1 lym- 
phoid cells  with (dashed  lines)  or without (solid  lines) also  being  given  polyI:C 
or were  left untreated (dotted  line). The groups contained  nine, eight, and 
six mice, respectively.  AU mice were then given two tail skin grafts, 
B6D2F1 (top) and SJL (bottom)  and graft survival  monitored  daily. Similar 
resuhs were  obtained  in an earlier  experiment  using fewer  graft recipients. 
culation and donor-specific response reduction were seen (Fig. 
1 C). Similarly, when SJL mice (low NK level) were infused 
with B6 lymphoid cells, both donor cell recirculation and 
donor-specific response reduction were seen (Fig. 1 D). How- 
ever, when the recipient SJL mice were also  treated with 
polyhC, the injected cells failed to recirculate, and also failed 
to induce response reduction (Fig.  1 E).  B6D2F1  cells in- 
jected into D2 mice both recirculate and induce donor-specific 
response reduction (Fig.  1 A). However, when the recipient 
mice were also injected with poly I:C, neither recirculation 
nor donor-specific response reduction was seen (Fig.  1 F). 
Enhanced Donor-specific Graft Survival Is Correlated with Donor 
Cell Recirculation.  D2  mice were infused with  3  x  107 
B6D2Ft lymphocytes and divided into two groups, one of 
which was treated with polyI:C as described. 4 d after donor 
cell infusion, tail skin grafting (B6D2Ft and SJL) was done 
on all these mice plus a third group of normal D2 mice age 
and  sex  matched  to  the  first  two  groups.  Fig.  2  shows 
significant enhancement of F1 (the infused antigen) but not 
SJL skin graft survival (third party) in the mice infused with 
B6D2F1  cell and not given polyI:C, but not in the other 
two groups. 
Discussion 
Intravenous injection of mice with viable allogeneic lym- 
phoid cells often, but not always, renders the recipient tolerant 
to the transplantation antigens carried by the donor lympho- 
cytes.  Although  MHC  differences are dearly implicated, 
detailed analysis of such differences between donor and host 
does not enable one to predict the outcome with complete 
accuracy. Often tolerance is not induced for situations in which 
the MHC differences predict it might have been (7). Thus, 
other factors must be involved. We show here that one of 
these factors, perhaps the decisive one, is whether the injected 
allogeneic cells can persist in the recirculating lymphocyte 
pool of the host. We further show that the extent of persis- 
tence is modulated by both genetic and environmental factors. 
Recipient mice were injected intravenously with allogeneic 
or semiallogeneic donor lymphoid calls differing from the 
recipient at both class I and class II MHC. For the combina- 
tions tested, we found that 3 d later there was a donor-specific 
reduction in the ability of the host to generate CTL in an 
in vitro MLR if and only if a significant fraction (at least 
one third compared with the same cells injected into a syn- 
geneic host) of the injected donor cells were still recirculating 
in the host (Fig.  1). Although tested less critically, the same 
criterion may also predict the long term survival of a donor 
skin graft (Fig.  2). 
Irrespective of their ultimate fate,  injected cells  appear 
capable of traversing from blood to LN. 1 d after injection, 
injected cells can be found in comparable frequencies in LN, 
spleen, and blood (Table  1). Disappearance from the recir- 
culating pool appears to be due to an active process mediated 
by the host. Mediators of this process could be either host 
NK cells,  host T  cells,  or host antibody. We feel the first 
to be most likely: 
(a) Injected cells can be removed very rapidly (Table 1) in 
a time shorter than that required for a specific host antidonor 
immune response to develop (21). 
(b) Cells injected into allogeneic athymic nude mice (few 
or no T cells but at least normal levels of NK cells [18]) are 
removed as effectively as in aUogeneic normal mice (Table 
2),  only consistent with removal by NK cells. 
(c) Cells from strain B mice injected into strain A  mice 
are removed much more rapidly than are Ft (A  x  B) ceUs. 
Host T cells or antibody should recognize B and F1 (A  x 
B) equivalently, or nearly so. See below for a discussion of 
how NK cells might make this distinction. 
(d) Persistence  of allogeneic ceils is more likely in hosts 
with low endogenous NK activity. In Fig.  1, compare the 
rapid removal of D2 cells in B6 (medium NK activity, refer- 
ence 18) with their persistence in B6-bg (very low NK ac- 
tivity, reference 17) or persistence of B6 cells in SJL hosts 
(low NK activity, reference 18). 
(e) Persistence of allogeneic cells can be increased by removal 
of NK cells. In Table 2, injection of B6 mice with antiasialo 
GM1 antibody greatly increased the persistence of injected 
D2 cells. These mice also showed a CTL response reduction 
against donor cells as in Fig.  1, but also had a reduced re- 
sponse against unrelated stimulators (data not shown), sug- 
gesting  that  antiasialo  GM1  antibody  reacts  with  CTL 
precursors as well as NK cells. We were unable to find a dose 
of antiasialo GM1 that permitted recirculation to continue 
without also having some effect on the response to unrelated 
stimulators (unpublished). 
(f)  Persistence  of allogeneic cells  can  be  decreased by 
boosting NK cell activity. In Fig.  1, injection of SJL mice 
with polyI:C, known to boost NK activity (20), led to the 
removal of injected B6 cells which otherwise would have per- 
sisted. In Table 3, injection of DBA/2 or B6 mice with polyI:C 
also led to the removal of B6D2F1  cells which otherwise 
would have persisted, but had no effect on the persistence 
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We conclude that, although circumstantial,  the evidence 
is quite strong that host NK cells are removing the injected 
cells. There is also evidence that the mechanism responsible 
for removing the cells is more effective at removing fully al- 
logeneic than semiallogeneic cells. 
NK cells can recognize and kill intravenously injected lym- 
phoid cells that lack class I MHC molecules carried by the 
NK cells (22, 23,  24). These observations  have been used 
to support the hypothesis  that NK cells recognize and re- 
spond to absence of self class I MHC molecules  (25, 26). 
This would explain why we found that fully allogeneic cells 
(e.g., B6 into D2) were rapidly removed, but predicts that 
semiallogeneic cells (e.g., B6D2F1 into D2) should not be 
removed at all, whereas we found they were removed after 
PolyI:C priming. 
Extensive studies have been made in the rat of what has 
been called allogeneic lymphocyte cytotoxicity (ALC) (27, 
28). Unsensitized rats injected with allogeneic viable lym- 
phocytes will start killing these lymphocytes within hours 
of injection. The effector cells are NK ceils. At least some 
target structures are linked (identical ?) to MHC molecules. 
In order of decreasing strength, destruction of injected cells 
is seen with inbred strain A recognizing strain B, F1 (A  x 
B) recognizing A, and A recognizing F, (A  x  B), with the 
extent of removal observed also being influenced by the genetic 
backgrounds of both the host and donor strains. The first 
two patterns can be explained by the missing sdf class I MHC 
modal (25, 26). The third cannot and is analogous  to our 
situation of injecting F, into parent.  In this third pattern, 
killing is much weaker and is not observed in many strain 
combinations (27). One can speculate that all three patterns 
of killing have a similar biological basis, perhaps resulting 
in some way from impaired sdf recognition (27, 29). 
It has been long established that performing multiple blood 
transfusions before kidney transplantation improves kidney 
graft survival in the human situation (30, 31). Recently, it 
has been shown that the donor blood must share at least one 
HLA-DR antigen with the recipient (32). Further, in in vitro 
studies, T cell unresponsiveness to donor cells was induced 
only if donor and recipient  shared one HLA haplotype or 
at least one HLA-B and HLA-DR antigen (33). We hypothe- 
size that this matching is required to enable the donor cells 
to persist in the recipient long enough to mediate response 
reduction. 
Rammensee and Hfigin (34) have reported that in vivo ad- 
ministration of anti-CD4 mAb before injection of allogeneic 
cells can enhance the ability of injected allogeneic cells to 
produce donor-specific response reduction in an MLK. More 
recently, Kitagama et al. (35) have reported that treatment 
of the recipient with either anti-CD8 or anti-CD4 enhances 
donor-specific response reduction either as measured in an 
MLR or as assessed by skin graft survival. Anti-CD4 was 
effective only if administered before allogeneic cell injection. 
Anti-CD8 was also effective when given later. It is hypothe- 
sized that these mAb treatments are affecting either the in- 
teractions between the infused allogeneic cells and host cells 
that can recognize them, or are directly removing host al- 
loreactive cells. Our results suggest  a third possibility  i.e., 
that the mAbs (particularly anti-CD4) may be enhancing sur- 
vival  of the  injected allogeneic  cells in  the  recirculating 
lymphocyte pool of the host by eliminating cells whose 
lymphokine production (particularly IFN-3' [20]) would up- 
regulate endogenous NK activity. 
Our studies have been done with strictly pathogen-free 
animals that should minimize environmental activation  of 
both NK cells and CD4 + cells. The widely variable results 
obtained by different groups studying donor-specific trans- 
fusion effects in very similar systems could reflect in part differ- 
ences in environmental activation  of host NK cells as well 
as strain-dependent  differences in NK activity that occur in- 
dependent of environmental factors. This reasoning leads to 
the prediction that appropriate selection of the MHC of the 
infused cells combined with a drug that blocked NK cell ac- 
tivation or, better still, blocked NK cell action, would pro- 
duce a profound enhancement in donor-specific  response reduc- 
tion and graft survival. 
The main conclusion of this study is that intravenously 
injected allogeneic lymphoid cells must persist in the recir- 
culating lymphocyte pool of the host to induce response reduc- 
tion. This conclusion is fully consistent  with the veto hy- 
pothesis (11-15) but does not rule out other mechanisms for 
explaining response reduction. Knowing that the persistence 
of the injected cells is greatly enhanced if they share MHC 
with the host, and that persistence can be reduced by host 
NK activity, should not only facilitate future studies of the 
phenomenon but enhance the prospects for its practical ap- 
plication. 
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